You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials

Article metrics

Article menu
Download PDFPDF
Oral Presentations
Abstract session: SLE and Sjögren's: new treatment options
OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials

 

Online download statistics by month:

Online download statistics by month: June 2015 to March 2024

AbstractFullPdf
Jun 20152802
Jul 20151804
Aug 20152805
Sep 20154912
Oct 20151101
Nov 20151405
Dec 20151400
Jan 20163503
Feb 20162604
Mar 20161601
Apr 20162602
May 20162702
Jun 20161601
Jul 20161102
Aug 20161501
Sep 20161801
Oct 2016600
Nov 20161700
Dec 20161100
Jan 20172201
Feb 20171900
Mar 20171402
Apr 20171405
May 2017300
Jun 2017500
Jul 2017802
Aug 20171201
Sep 2017800
Oct 2017800
Nov 20175602
Dec 20172001
Jan 2018800
Feb 2018601
Mar 20181400
Apr 20181000
May 2018800
Jun 20181000
Jul 2018800
Aug 20181000
Sep 2018200
Oct 2018600
Nov 20182202
Dec 2018200
Feb 2019800
Mar 2019300
Apr 2019400
May 2019601
Jun 2019400
Jul 2019900
Aug 2019400
Sep 2019400
Nov 2019400
Dec 20191600
Jan 2020200
Feb 2020200
Mar 2020700
Apr 20201200
May 20201200
Jun 2020800
Jul 2020800
Aug 20201501
Sep 20201800
Oct 2020200
Nov 20201002
Dec 2020400
Jan 2021600
Feb 2021800
Apr 20211400
May 2021400
Aug 2021100
Sep 2021102
Oct 2021400
Nov 20211600
Dec 20211600
Jan 2022600
Feb 2022200
Mar 20221000
Apr 20221800
May 20221100
Jun 2022900
Jul 20221100
Aug 20221200
Sep 20221100
Oct 2022801
Nov 20221100
Dec 2022900
Jan 20231300
Feb 20232100
Mar 20231100
Apr 20231000
May 20231000
Jun 2023500
Jul 2023400
Aug 2023500
Sep 2023600
Oct 2023200
Nov 20231500
Dec 20232400
Jan 2024700
Feb 20241100
Mar 20242100
Total1196160